Document:

Exhibit 4.19

 

Execution Version

 

 

Second Amendment Agreement

relating to the Facility Agreement dated July 28, 2014

between

Affimed GmbH

as Borrower

and

Affimed N.V.

as Dutch Guarantor

and

Perceptive Credit Opportunities Fund, LP

as Lender

 

 

 

    	 

    	 

    

This AMENDMENT AGREEMENT (the “Agreement”)
is made between:

 

		(1)	Affimed GmbH (former Affimed Therapeutics AG), a company incorporated as a limited liability
corporation (Gesellschaft mit beschränkter Haftung) incorporated under the laws of the Federal Republic of Germany,
registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Mannheim, Germany under
HRB 721206 and having its business address at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany,

 

- hereinafter referred to as “Borrower”
-

 

		(2)	Affimed N.V., a company incorporated as a stock corporation (naamloze vennootschap)
incorporated under the laws of the Netherlands, registered with the commercial register of the Netherlands under 60673389 and having
its business address at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany,

 

- hereinafter referred to as “Dutch
Guarantor” -

 

		(3)	Perceptive Credit Opportunities Fund, LP, a limited partnership, established and validly
existing under the laws of Delaware, United States, with its business address at 499 Park Avenue, 25th Floor, New York, New York
10022,

 

- hereinafter referred to as “Lender”
-

 

- The Borrower, the Dutch Guarantor and the
Lender are together referred to as the “Parties”, each as a “Party” -

 

    	 1

 

     

    

Preamble

 

		(A)	On July 28, 2014 the Borrower and PCOF 1, LLP, a limited liability company governed by the laws
of Delaware, having its business address at 499 Park Avenue, 25th Floor, New York, New York 10022 (“Original Lender”)
as lender entered into a facility agreement (“Facility Agreement”), a U.S. IP Security Agreement (“U.S.
Security Agreement”), a Global Assignment Agreement and several other security agreements (U.S. Security Agreement, Global
Assignment Agreement and the other security agreements together the “Security Agreements”; the Facility Agreement
and the Security Agreements also jointly referred to as “Finance Documents”) (Notarial deed dated July 28, 2014
with notarial deed number 2569V/2014 of the notary Dr. Hans-Joachim Vollrath) by which the Original Lender provided to the Borrower
a facility in the amount of USD 5,500,000.00 (“Facility A”) and a facility in the amount of USD 8,500,000.00
(“Facility B”).

 

		(B)	On September 19, 2014 the Dutch Guarantor acceded to the Facility Agreement as a guarantor.

 

		(C)	On October 6, 2014 the Dutch Guarantor and the Original Lender entered into a warrant agreement
in regard to 106,250 shares in the Dutch Guarantor in favor of the Original Lender (“Dutch Warrant”).

 

		(D)	On December 4, 2014 the Original Lender, the Borrower and the Dutch Guarantor entered into several
transfer agreements (Notarial deed dated December 4, 2014 with notarial deed number 4058V/14 of the notary Dr. Hans-Joachim Vollrath)
by which the Original Lender transferred the Facility Agreement and the Security Agreements by way of assumption of contracts (Vertragsübernahme)
to the Lender. At the same date the Original Lender transferred, by Deed of Transfer dated December 12, 2014, the Dutch Warrant
to the Lender.

 

		(E)	In April 2015 the Borrower established Affimed Inc., a stock corporation under US law (“Affimed
Inc.”). On April 29, 2015 the Lender and the Borrower entered into an amendment agreement to the Facility Agreement by
which the Lender approved a financing of Affimed Inc. by the Borrower up to an amount of USD 100,000.

 

		(F)	In 2014 and 2015 Borrower filed new patent applications with the European Patent Office and the
USPTO indicated as “Cross-Reactive CD3”, “Trispecifics” and “Combination AFM13 and CPI” (described
in Annex F) (“New Patents”). Upon request of the Borrower, the Lender intends to waive the Borrowers obligation
under the Finance Documents, as defined in the Facility Agreement, to pledge the New Patents to the Lender.

 

		(G)	The Borrower’s obligation under the Finance Documents to pledge, assign or otherwise provide
security regarding the Borrower’s future intellectual property rights shall be amended as follows: With regard to the Borrower’s
intellectual property rights which will be applied for, filed for registration or otherwise come into existence after the date
hereof (“Future IP Rights”), the Borrower’s obligation under the Finance Documents shall be subject to
the Lender’s request, and if such request is not made, be deemed to have been waived by the Lender.

 

    	 2

 

     

    

		(H)	Furthermore, the Parties intend to agree that the Availability Period, as defined in the Facility
Agreement, in relation to Facility B shall lapse on June 30, 2015.

 

		(I)	Additionally, the Certificate of the Dutch Warrant, currently naming the Original Lender as “Holder”,
shall be exchanged against an identical warrant certificate naming the Lender as “Holder”.

 

NOW, THEREFORE, the Parties agree as follows:

 

		1.	AMENDMENT TO THE FACILITY AGREEMENT

 

The Facility Agreement shall hereby be
amended and restated as follows:

 

		1.1	In Section 1, Clause 1.1 Definitions, page 4, the following definition of the term Availability
Period:

 

“Availability Period”
means:

 

		(a)	in relation to Facility A, the period from and including the date of this Agreement to and including
December 31, 2015; and

 

		(b)	in relation to Facility B, the period from and including November 1, 2014 to and including December
31, 2015.”

 

shall be replaced by the following
wording:

 

“Availability Period”
means:

 

		(c)	in relation to Facility A, the period from and including the date of this Agreement to and including
December 31, 2015; and

 

		(d)	in relation to Facility B, the period from and including November 1, 2014 to and including June
30, 2015.”

 

		1.2	Section 5, Clause 10.1.1, page 25 with the wording

 

	“10.1.1	Beginning on November 1, 2014, the Borrower shall pay to the Lender a fee of one per cent (1%) per annum on that Lender’s Available Commitment. For the avoidance of doubt, no commitment fee shall apply after December 31, 2015.”

shall be replaced by the following
wording:

 

	“10.1.1	Beginning on November 1, 2014, the Borrower shall pay to the Lender a fee of one per cent (1%) per annum on that Lender’s Available Commitment. For the avoidance of doubt, no commitment fee shall apply after June 30, 2015.”

 

		1.3	The provisions of the Facility Agreement shall, save as amended by this Agreement, continue in
full force and effect.

 

    	 3

 

     

    

		2.	WAIVER REGARDING NEW PATENTS

 

		2.1	The Lender hereby waives any pledge, assignment or similar security and any obligation of the Borrower
under the Finance Documents to pledge, assign or grant any other security regarding the New Patents to the Lender as collateral.
The Borrower accepts the aforementioned waiver. All other obligations thereunder, especially the restriction not to pledge intellectual
property rights, including the New Patents, to a third party, remain in full force and effect and shall not be waived hereby.

 

		2.1	The Borrower’s obligation under the Finance Documents to pledge, assign or otherwise provide
security regarding a Future IP Right as well as any pledge, assignment or other security regarding the respective Future IP Right
shall be deemed to be waived by the Lender if:

 

		2.1.1	The Borrower has notified the Lender of such Future IP Right without undue delay after such individual
Future IP Right has been applied for, filed for registration or otherwise come into existence (“Notification”);
and

 

		2.1.2	The Lender has not requested the Borrower to pledge, assign or otherwise provide security regarding
such notified Future IP Right within ten Business Days (as defined in the Facility Agreement) after such Notification has been
received by the Lender.

 

The aforementioned waiver shall
only apply to the specific Future IP Right as listed and provided with a reasonable satisfactory description in the Notification.
For the avoidance of doubt, in case the Borrower does not, or does not correctly notify the Lender of a Future IP Right, the Borrower’s
obligation to pledge, assign or otherwise provide security regarding the same continues to exist.

 

		3.	UNDERTAKING

 

		3.1	The Dutch Guarantor shall ensure that within four (4) weeks after signing of this Agreement, the
Lender receives, in exchange for the current certificate of the Dutch Warrant, a warrant certificate with regard to 106,250 shares
in the Dutch Guarantor (“New Warrant Certificate”), which is identical to the current certificate of the Dutch
Warrant, except that instead of the Original Lender the Lender is named as “Holder” in such certificate.

 

		3.2	The Dutch Guarantor shall, to the reasonable satisfaction of the Lender, provide the New Warrant
Certificate pursuant to 3.1. The Dutch Guarantor has provided a written statement from an independent legal counsel of the Dutch
Guarantor confirming that the Legal Opinion dated October 7, 2014, also applies to the New Warrant Certificate and consequently,
can still be relied upon by the Lender.

 

		4.	TRANSACTION EXPENSES

 

The Borrower shall bear all costs
and expenses (including legal fees) incurred in connection with the negotiation, preparation, and execution of this Agreement and
any other documents referred to in this Agreement.

 

    	 4

 

     

    

		5.	NOTICES AND COMMUNICATION

 

Any communication to be made
under or in connection with this Agreement shall be made in writing and, unless otherwise stated, may be made by fax or overnight
courier to the following addresses:

 

if directed to the Borrower, to:

 

Affimed GmbH

Technologiepark, Im Neuenheimer Feld 582

69120 Heidelberg, Germany

Attn: Dr. Florian Fischer

Fax: +49 6221 65307 77

Email: f.fischer@affimed.com

 

with a copy to

 

CMS Hasche Sigle

Partnerschaft von Rechtsanwälten und Steuerberatern mbB

Nymphenburger Straße 12

80335 Munich, Germany

Attn: Stefan-Ulrich Müller

Fax: +49 89 23807 40667

Email: Stefan-Ulrich.Mueller@cmshs.com

 

if directed to the Dutch Guarantor, to:

 

Affimed N.V.

 

Technologiepark, Im Neuenheimer Feld 582

69120 Heidelberg, Germany

Attn: Dr. Florian Fischer

Fax: +49 6221 65307 77

Email: f.fischer@affimed.com

 

with a copy to

 

CMS Hasche Sigle

Partnerschaft von Rechtsanwälten und Steuerberatern mbB

Nymphenburger Straße 12

80335 Munich, Germany

Attn: Stefan-Ulrich Müller

Fax: +49 89 23807 40667

Email: Stefan-Ulrich.Mueller@cms-hs.com

 

if directed to the Lender, to:

 

Perceptive Advisors LLC

499 Park Avenue, 25th Floor

New York, New York 10022

United States of America

 

    	 5

 

     

    

Attn: Sandeep Dixit

Email: Sandeep@perceptivelife.com

 

with a copy to:

 

Morrison & Foerster LLP

Potsdamer Platz 1

10785 Berlin, Germany

Attn: Jörg Meißner

Fax: +49 30 726 221 130

Email: jmeissner@mofo.com

 

		6.	MISCELLANEOUS

 

		6.1	If provisions in this Agreement include English terms after which German terms or Dutch terms have
been inserted in brackets and/or italics, the respective German terms or Dutch term alone and not the English terms shall be decisive
for the interpretation of the respective provisions.

 

		6.2	Any amendment or supplement to or modification of this Agreement, including this provision, shall
be valid only if made in writing, except where a stricter form (e.g., notarization) is required under applicable mandatory law.

 

		6.3	Should any provision of this Agreement be or become, or be deemed to be or become, invalid or unenforceable
as a whole or in part, the validity and enforceability of the remaining provisions shall not be affected thereby. Any such invalid
or unenforceable provision shall be replaced by such valid and enforceable provision as comes closest to the economic intent and
purpose of such invalid or unenforceable provision. The same shall apply in the event that this Agreement contains any gaps (Vertragslücken).

 

		6.4	This Agreement is governed by the laws of the Federal Republic of Germany. Any non-contractual
rights and obligations arising out of or in connection with this Agreement shall also be governed by the laws of the Federal Republic
of Germany.

 

		6.5	The courts of Frankfurt am Main have exclusive jurisdiction to settle any dispute arising out of
or in connection with this Agreement (including a dispute regarding the existence, validity or termination of this Agreement).

 

[Signature page follows the next page]

 

    	 6

 

     

    

 

Affimed GmbH

	

in its capacity as Borrower	 	 
	Place/Date:	Heidelberg, August 14, 2015	 	Place/Date:	Heidelberg, August 14, 2015
	 	 	 
	/s/  Dr. Adi Hoess	 	/s/  Dr. Florian Fischer
	Name:	Dr. Adi Hoess	 	Name:	Dr. Florian Fischer
	Function:	Chief Executive Officer	 	Function:	Chief Financial Officer
	 	 	 	 	 	 	 

 

 

	Affimed N.V.

in its capacity as Dutch Guarantor	 	 
	Place/Date:	Heidelberg, August 14, 2015	 	Place/Date:	Heidelberg, August 14, 2015
	 	 	 
	/s/  Dr. Adi Hoess	 	/s/  Dr. Florian Fischer
	Name:	Dr. Adi Hoess	 	Name:	Dr. Florian Fischer
	Function:	Chief Executive Officer	 	Function:	Chief Financial Officer
	 	 	 	 	 	 	 

 

 

	Perceptive Credit Opportunities Fund, LP
 
 in its capacity as Lender
 
 by:  Perceptive Credit Opportunities GP, LLC, its general partner

                                              

	 
	Place/Date:	New York, August 14, 2015	 
	 	 
	/s/  Joseph Edelman	 

	Name:	Joseph Edelman	 
	Function:	Chief Executive Officer & Portfolio Manager

 

    	 7Exhibit 4.20

 

 

 

 

	Affimed
                           GmbH   Affimed N.V.  
                           Im Neuenheimer Feld 582   69120 Heidelberg

         

        

        

         

        Perceptive Credit
        Opportunities Fund, LP

        Mr. Edelman

        

        51 Astor Place

        

        10th Floor

        

        New York

        New York 10003

USA

         
	
	 	 

March
29, 2016

 

 

Term Facility Agreement dated
July 24, 2014 

Waiver regarding a Development
Milestone (Clause 19.2) 

 

 

Dear Mr. Edelman,

 

We are writing to you on behalf
of Affimed GmbH and on behalf of Affimed N.V. As discussed with Sam Chawla and Sandeep Dixit, we are contemplating to discuss
with you the structure and certain terms of the Term Facility Agreement between Affimed GmbH (formerly Affimed Therapeutics AG,
the “Company”) as Borrower, Affimed N.V. as Guarantor and funds managed by Perceptive Advisors LLC –
currently Perceptive Credit Opportunities Fund, LP and PCOF Phoenix II Fund, LP – as Lenders, dated July 24, 2014 (as amended
from time to time, the “Agreement”). In connection therewith and in order to better reflect the Company’s
current development strategy, the Parties might also agree on development milestones other or different than those currently set-out
in Schedule 6 to the Agreement.

 

To allow
for sufficient time for the above mentioned discussions, the Lender hereby agrees to waive, up and until September 30, 2016, any
rights it may have under Section 21.13 (Events of Default, Other obligations) of the Agreement in connection with 19.2 (Development
of Milestones) and Schedule 6, No. 2 of the Agreement. For the avoidance of doubt, all other rights and obligations of the Parties
under the Agreement remain unaffected, in particular, but not limited to, the Lender’s rights under Section 21.13 (Events
of Default, Other obligations) in case of any non-compliance with any provision of the Finance Documents other than 19.2 (Development
of Milestones), Schedule 6, No. 2.

 

Terms defined in the Agreement
have the same meaning in this letter, unless otherwise defined herein. This letter is governed by German law.

 

 

 

 

	Affimed GmbH	 	 	 
	Affimed
    N.V.	Phone:
    +49 6221 65307 0	Bankverbindung: Deutsche
    Bank	Geschäftsführer
    der Affimed GmbH:
	Technologiepark	Fax:
    +49 6221 65307 49	IBAN  DE
    5867 2700 0300 1408 0600	Dr. Adi Hoess
	Im
    Neuenheimer Feld 582	www.affimed.com	BIC  DEUTDESM672	Dr. Florian Fischer
	69120
    Heidelberg	E-Mail: info@affimed.com	Sitz der Gesellschaft:
    Heidelberg	Dr. Jens-Peter Marschner
	Germany	 	Registergericht: Amtsgericht
    Mannheim	Dr. Martin Treder
	 	 	HRB 721206 –
    VAT.Nr.: DE 206700144	Dr. Jörg Windisch

 

    	 

    	 

    

 

 

Please return countersigned copies
of this letter to Affimed GmbH and to Affimed N.V. at your earliest convenience.

 

Kind regards

 

 

On behalf of Affimed GmbH:

 

March 29, 2016

Date

 

	/s/ Adi Hoess	 	/s/
    Florian Fischer
	Dr.
    Adi Hoess 	 	Dr. Florian Fischer
	CEO
    	 	CFO

 

 

 

 

On behalf of Affimed N.V.

 

March 29, 2016

Date

 

	/s/ Adi Hoess	 	/s/
    Florian Fischer
	Dr.
    Adi Hoess 	 	Dr. Florian Fischer
	CEO
    	 	CFO

 

 

 

 

 

	Affimed GmbH	 	 	 
	Affimed
    N.V.	Phone:
    +49 6221 65307 0	Bankverbindung: Deutsche
    Bank	Geschäftsführer
    der Affimed GmbH:
	Technologiepark	Fax:
    +49 6221 65307 49	IBAN  DE
    5867 2700 0300 1408 0600	Dr. Adi Hoess
	Im
    Neuenheimer Feld 582	www.affimed.com	BIC  DEUTDESM672	Dr. Florian Fischer
	69120
    Heidelberg	E-Mail: info@affimed.com	Sitz der Gesellschaft:
    Heidelberg	Dr. Jens-Peter Marschner
	Germany	 	Registergericht: Amtsgericht
    Mannheim	Dr. Martin Treder
	 	 	HRB 721206 –
    VAT.Nr.: DE 206700144	Dr. Jörg Windisch

 

    	 

    	 

    

 

 

Accepted and Agreed

 

On behalf of Perceptive Credit
Opportunities Fund, LP

And PCOF Phoenix II Fund, LP

 

March 29, 2016

Date

 

	/s/ Joseph Edelman

Joseph Edelman

 

 

 

 

 

 

 

 

 

 

	Affimed GmbH	 	 	 
	Affimed
    N.V.	Phone:
    +49 6221 65307 0	Bankverbindung: Deutsche
    Bank	Geschäftsführer
    der Affimed GmbH:
	Technologiepark	Fax:
    +49 6221 65307 49	IBAN  DE
    5867 2700 0300 1408 0600	Dr. Adi Hoess
	Im
    Neuenheimer Feld 582	www.affimed.com	BIC  DEUTDESM672	Dr. Florian Fischer
	69120
    Heidelberg	E-Mail: info@affimed.com	Sitz der Gesellschaft:
    Heidelberg	Dr. Jens-Peter Marschner
	Germany	 	Registergericht: Amtsgericht
    Mannheim	Dr. Martin Treder
	 	 	HRB 721206 –
    VAT.Nr.: DE 206700144	Dr. Jörg Windisch

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]